Cargando…
Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
BACKGROUND: A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women. Consistent gel use is, however, of great importance to ensure continued protection against HIV infection, even with a safe and effective microbicide. We assessed the long-term correlates of con...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564905/ https://www.ncbi.nlm.nih.gov/pubmed/23374729 http://dx.doi.org/10.1186/1745-6215-14-33 |
_version_ | 1782258380774047744 |
---|---|
author | Abaasa, Andrew Crook, Angela Gafos, Mitzy Anywaine, Zacchaeus Levin, Jonathan Wandiembe, Symon Nanoo, Ananta Nunn, Andrew McCormack, Sheena Hayes, Richard Kamali, Anatoli |
author_facet | Abaasa, Andrew Crook, Angela Gafos, Mitzy Anywaine, Zacchaeus Levin, Jonathan Wandiembe, Symon Nanoo, Ananta Nunn, Andrew McCormack, Sheena Hayes, Richard Kamali, Anatoli |
author_sort | Abaasa, Andrew |
collection | PubMed |
description | BACKGROUND: A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women. Consistent gel use is, however, of great importance to ensure continued protection against HIV infection, even with a safe and effective microbicide. We assessed the long-term correlates of consistent gel use in the MDP 301 clinical trial among HIV-negative women in sero-discordant couples in south-west Uganda. METHODS: HIV-negative women living with an HIV-infected partner were enrolled between 2005 and 2008, in a three-arm phase III microbicide trial and randomized to 2% PRO2000, 0.5% PRO2000 or placebo gel arms. Follow-up visits continued up to September 2009. The 2% arm was stopped early due to futility and the 229 women enrolled in this arm were excluded from this analysis. Data were analyzed on 544 women on the 0.5% and placebo arms who completed at least 52 weeks of follow-up, sero-converted or became pregnant before 52 weeks. Consistent gel use was defined as satisfying all of the following three conditions: (i) reported gel use at the last sex act for at least 92% of the 26 scheduled visits or at least 92% of the visits attended if fewer than 26; (ii) at least one used applicator returned for each visit for which gel use was reported at the last sex act; (iii) attended at least 13 visits (unless the woman sero-converted or became pregnant during follow-up). Logistic regression models were fitted to investigate factors associated with consistent gel use. RESULTS: Of the 544 women, 473 (86.9%) were followed for at least 52 weeks, 29 (5.3%) sero-converted and 42 (7.7%) became pregnant before their week 52 visit. Consistent gel use was reported by 67.8%. Women aged 25 to 34 years and those aged 35 years or older were both more than twice as likely to have reported consistently using gel compared to women aged 17 to 24 years. Living in a household with three or more rooms used for sleeping compared to one room was associated with a twofold increase in consistent gel use. CONCLUSION: In rural Uganda younger women and women in houses with less space are likely to require additional support to achieve consistent microbicide gel use. TRIAL REGISTRATION: Protocol Number ISRCTN64716212 |
format | Online Article Text |
id | pubmed-3564905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35649052013-02-08 Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda Abaasa, Andrew Crook, Angela Gafos, Mitzy Anywaine, Zacchaeus Levin, Jonathan Wandiembe, Symon Nanoo, Ananta Nunn, Andrew McCormack, Sheena Hayes, Richard Kamali, Anatoli Trials Research BACKGROUND: A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women. Consistent gel use is, however, of great importance to ensure continued protection against HIV infection, even with a safe and effective microbicide. We assessed the long-term correlates of consistent gel use in the MDP 301 clinical trial among HIV-negative women in sero-discordant couples in south-west Uganda. METHODS: HIV-negative women living with an HIV-infected partner were enrolled between 2005 and 2008, in a three-arm phase III microbicide trial and randomized to 2% PRO2000, 0.5% PRO2000 or placebo gel arms. Follow-up visits continued up to September 2009. The 2% arm was stopped early due to futility and the 229 women enrolled in this arm were excluded from this analysis. Data were analyzed on 544 women on the 0.5% and placebo arms who completed at least 52 weeks of follow-up, sero-converted or became pregnant before 52 weeks. Consistent gel use was defined as satisfying all of the following three conditions: (i) reported gel use at the last sex act for at least 92% of the 26 scheduled visits or at least 92% of the visits attended if fewer than 26; (ii) at least one used applicator returned for each visit for which gel use was reported at the last sex act; (iii) attended at least 13 visits (unless the woman sero-converted or became pregnant during follow-up). Logistic regression models were fitted to investigate factors associated with consistent gel use. RESULTS: Of the 544 women, 473 (86.9%) were followed for at least 52 weeks, 29 (5.3%) sero-converted and 42 (7.7%) became pregnant before their week 52 visit. Consistent gel use was reported by 67.8%. Women aged 25 to 34 years and those aged 35 years or older were both more than twice as likely to have reported consistently using gel compared to women aged 17 to 24 years. Living in a household with three or more rooms used for sleeping compared to one room was associated with a twofold increase in consistent gel use. CONCLUSION: In rural Uganda younger women and women in houses with less space are likely to require additional support to achieve consistent microbicide gel use. TRIAL REGISTRATION: Protocol Number ISRCTN64716212 BioMed Central 2013-02-01 /pmc/articles/PMC3564905/ /pubmed/23374729 http://dx.doi.org/10.1186/1745-6215-14-33 Text en Copyright ©2013 Abaasa et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Abaasa, Andrew Crook, Angela Gafos, Mitzy Anywaine, Zacchaeus Levin, Jonathan Wandiembe, Symon Nanoo, Ananta Nunn, Andrew McCormack, Sheena Hayes, Richard Kamali, Anatoli Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda |
title | Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda |
title_full | Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda |
title_fullStr | Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda |
title_full_unstemmed | Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda |
title_short | Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda |
title_sort | long-term consistent use of a vaginal microbicide gel among hiv-1 sero-discordant couples in a phase iii clinical trial (mdp 301) in rural south-west uganda |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564905/ https://www.ncbi.nlm.nih.gov/pubmed/23374729 http://dx.doi.org/10.1186/1745-6215-14-33 |
work_keys_str_mv | AT abaasaandrew longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT crookangela longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT gafosmitzy longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT anywainezacchaeus longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT levinjonathan longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT wandiembesymon longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT nanooananta longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT nunnandrew longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT mccormacksheena longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT hayesrichard longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda AT kamalianatoli longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda |